Galderma Secures ‘BBB’ Credit Rating With Positive Outlook from S&P Global Ratings

Contributed by: Business Wire

Logo

Tags

Professional Services

Health

Other Health

Finance

Pharmaceutical

Biotechnology

S&P Global Ratings

More Like This

Galderma Delivers Record Net Sales of 3.737 Billion USD in the First Nine Months of 2025 and 15.0% Year-on-Year Growth at Constant Currency, Raises Full-Year Guidance

Galderma Delivers a Strong Start to the Year With Record Net Sales of Over 1 Billion USD for the First Quarter and 12.4% Year-on-Year Growth

Galderma Completes Successful Placement of CHF 175 Million Bond

EADV 2025: Galderma Reinforces Leadership in Dermatology With Latest Advances in Sensitive Skin and Itch

Galderma Announces Full Exercise of Over-Allotment Option

Securitas AB upgraded to 'BBB' by S&P Global Ratings

EQT AB assigned 'A-' (Stable) credit rating by S&P

Galderma Granted Key Manufacturing License Updates for New Biologics Capabilities at Its Center of Excellence